Pfizer Raises and Narrows Full-Year EPS Outlook as Eliquis Strength Supports Q3 Beat

Core Insights - Pfizer has raised and tightened its full-year earnings guidance for the second consecutive quarter, driven by strong demand for its Eliquis blood thinner and a recovery in cardiovascular therapies [1][2] - The company increased its annual diluted EPS range to $3.00 to $3.15 from $2.90 to $3.10, while reaffirming full-year revenue expectations of $61 billion to $64 billion [1] Financial Performance - Adjusted EPS for the third quarter was $0.87, exceeding expectations of $0.63, with revenue of $16.65 billion, also surpassing the forecast of $16.59 billion [2] - Eliquis sales increased by 22% to $2.02 billion, supported by higher demand for heart disease medications [2] Strategic Developments - The company is actively cutting costs and launching new products while managing litigation related to Metsera, including lawsuits concerning Novo Nordisk's unsolicited bid following Pfizer's previous $7.3 billion agreement [2] - Pfizer's agreement with the U.S. administration to lower Medicare drug prices in exchange for three years of tariff relief is expected to provide greater policy visibility [2]